Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer

Shyr Ming Sheen-Chen, Hock Liew Eng, Chih Wei Sheen, Yu Fan Cheng, Fong Fu Chou, Wei Jen Chen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. The outcome of breast cancer is usually determined by multiple factors. Circulating intercellular adhesion molecule-1 has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim of evaluating the prognostic significance of circulating intercellular adhesion molecule-1 in breast cancer. Methods and Material: From December 1994 to May 1995, 50 patients with invasive breast carcinoma were included. Venous blood samples were collected before surgery and the serum levels of circulating intercellular adhesion molecule-1 were measured with an enzyme immunoassay method. The data of maximum tumor size, age, estrogen receptor status, lymph node status and TNM staging were collected and evaluated simultaneously with the serum levels of circulating intercellular adhesion molecule-1. Fifteen healthy subjects were used as control group. Results: The mean value of circulating intercellular adhesion molecule-1 in patient group was 463 ± 92 ng/ml and that of the control group was 346 ± 68 ng/ml and the difference was significant (p < 0.01). In univariable analysis, patients with maximum tumor size of 5 cm or greater (p < 0.01), mol e advanced lymph node status (p < 0.01) and more advanced TNM staging (p < 0.01) were shown to have significantly higher serum levels of circulating intercellular adhesion molecule-1. However, in multivariable analysis, TNM staging was demonstrated to be the only independent factor (p < 0.01) related to significant higher serum level of circulating intercellular adhesion molecule-1. Conclusion: Preoperative serum levels of circulating intercellular adhesion molecule-1 may reflect the severity of staging for invasive breast cancel and may be a promising, additive predictor which deserves further investigation.

Original languageEnglish
Pages (from-to)2823-2826
Number of pages4
JournalAnticancer Research
Volume17
Issue number4 A
Publication statusPublished - Sep 3 1997
Externally publishedYes

Fingerprint

Intercellular Adhesion Molecule-1
Breast Neoplasms
Serum
Neoplasm Staging
Lymph Nodes
Neoplasms
Control Groups
Immunoenzyme Techniques
Estrogen Receptors
Healthy Volunteers
Breast

Keywords

  • Breast cancer
  • Intercellular adhesion molecule-1
  • Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sheen-Chen, S. M., Eng, H. L., Sheen, C. W., Cheng, Y. F., Chou, F. F., & Chen, W. J. (1997). Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. Anticancer Research, 17(4 A), 2823-2826.

Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. / Sheen-Chen, Shyr Ming; Eng, Hock Liew; Sheen, Chih Wei; Cheng, Yu Fan; Chou, Fong Fu; Chen, Wei Jen.

In: Anticancer Research, Vol. 17, No. 4 A, 03.09.1997, p. 2823-2826.

Research output: Contribution to journalArticle

Sheen-Chen, SM, Eng, HL, Sheen, CW, Cheng, YF, Chou, FF & Chen, WJ 1997, 'Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer', Anticancer Research, vol. 17, no. 4 A, pp. 2823-2826.
Sheen-Chen, Shyr Ming ; Eng, Hock Liew ; Sheen, Chih Wei ; Cheng, Yu Fan ; Chou, Fong Fu ; Chen, Wei Jen. / Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. In: Anticancer Research. 1997 ; Vol. 17, No. 4 A. pp. 2823-2826.
@article{18d64954ca3e430baa43aaec08b05b8a,
title = "Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer",
abstract = "Background. The outcome of breast cancer is usually determined by multiple factors. Circulating intercellular adhesion molecule-1 has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim of evaluating the prognostic significance of circulating intercellular adhesion molecule-1 in breast cancer. Methods and Material: From December 1994 to May 1995, 50 patients with invasive breast carcinoma were included. Venous blood samples were collected before surgery and the serum levels of circulating intercellular adhesion molecule-1 were measured with an enzyme immunoassay method. The data of maximum tumor size, age, estrogen receptor status, lymph node status and TNM staging were collected and evaluated simultaneously with the serum levels of circulating intercellular adhesion molecule-1. Fifteen healthy subjects were used as control group. Results: The mean value of circulating intercellular adhesion molecule-1 in patient group was 463 ± 92 ng/ml and that of the control group was 346 ± 68 ng/ml and the difference was significant (p < 0.01). In univariable analysis, patients with maximum tumor size of 5 cm or greater (p < 0.01), mol e advanced lymph node status (p < 0.01) and more advanced TNM staging (p < 0.01) were shown to have significantly higher serum levels of circulating intercellular adhesion molecule-1. However, in multivariable analysis, TNM staging was demonstrated to be the only independent factor (p < 0.01) related to significant higher serum level of circulating intercellular adhesion molecule-1. Conclusion: Preoperative serum levels of circulating intercellular adhesion molecule-1 may reflect the severity of staging for invasive breast cancel and may be a promising, additive predictor which deserves further investigation.",
keywords = "Breast cancer, Intercellular adhesion molecule-1, Serum",
author = "Sheen-Chen, {Shyr Ming} and Eng, {Hock Liew} and Sheen, {Chih Wei} and Cheng, {Yu Fan} and Chou, {Fong Fu} and Chen, {Wei Jen}",
year = "1997",
month = "9",
day = "3",
language = "English",
volume = "17",
pages = "2823--2826",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 A",

}

TY - JOUR

T1 - Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer

AU - Sheen-Chen, Shyr Ming

AU - Eng, Hock Liew

AU - Sheen, Chih Wei

AU - Cheng, Yu Fan

AU - Chou, Fong Fu

AU - Chen, Wei Jen

PY - 1997/9/3

Y1 - 1997/9/3

N2 - Background. The outcome of breast cancer is usually determined by multiple factors. Circulating intercellular adhesion molecule-1 has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim of evaluating the prognostic significance of circulating intercellular adhesion molecule-1 in breast cancer. Methods and Material: From December 1994 to May 1995, 50 patients with invasive breast carcinoma were included. Venous blood samples were collected before surgery and the serum levels of circulating intercellular adhesion molecule-1 were measured with an enzyme immunoassay method. The data of maximum tumor size, age, estrogen receptor status, lymph node status and TNM staging were collected and evaluated simultaneously with the serum levels of circulating intercellular adhesion molecule-1. Fifteen healthy subjects were used as control group. Results: The mean value of circulating intercellular adhesion molecule-1 in patient group was 463 ± 92 ng/ml and that of the control group was 346 ± 68 ng/ml and the difference was significant (p < 0.01). In univariable analysis, patients with maximum tumor size of 5 cm or greater (p < 0.01), mol e advanced lymph node status (p < 0.01) and more advanced TNM staging (p < 0.01) were shown to have significantly higher serum levels of circulating intercellular adhesion molecule-1. However, in multivariable analysis, TNM staging was demonstrated to be the only independent factor (p < 0.01) related to significant higher serum level of circulating intercellular adhesion molecule-1. Conclusion: Preoperative serum levels of circulating intercellular adhesion molecule-1 may reflect the severity of staging for invasive breast cancel and may be a promising, additive predictor which deserves further investigation.

AB - Background. The outcome of breast cancer is usually determined by multiple factors. Circulating intercellular adhesion molecule-1 has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim of evaluating the prognostic significance of circulating intercellular adhesion molecule-1 in breast cancer. Methods and Material: From December 1994 to May 1995, 50 patients with invasive breast carcinoma were included. Venous blood samples were collected before surgery and the serum levels of circulating intercellular adhesion molecule-1 were measured with an enzyme immunoassay method. The data of maximum tumor size, age, estrogen receptor status, lymph node status and TNM staging were collected and evaluated simultaneously with the serum levels of circulating intercellular adhesion molecule-1. Fifteen healthy subjects were used as control group. Results: The mean value of circulating intercellular adhesion molecule-1 in patient group was 463 ± 92 ng/ml and that of the control group was 346 ± 68 ng/ml and the difference was significant (p < 0.01). In univariable analysis, patients with maximum tumor size of 5 cm or greater (p < 0.01), mol e advanced lymph node status (p < 0.01) and more advanced TNM staging (p < 0.01) were shown to have significantly higher serum levels of circulating intercellular adhesion molecule-1. However, in multivariable analysis, TNM staging was demonstrated to be the only independent factor (p < 0.01) related to significant higher serum level of circulating intercellular adhesion molecule-1. Conclusion: Preoperative serum levels of circulating intercellular adhesion molecule-1 may reflect the severity of staging for invasive breast cancel and may be a promising, additive predictor which deserves further investigation.

KW - Breast cancer

KW - Intercellular adhesion molecule-1

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=0030856954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030856954&partnerID=8YFLogxK

M3 - Article

C2 - 9252723

AN - SCOPUS:0030856954

VL - 17

SP - 2823

EP - 2826

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 A

ER -